doi: 10.3389/fped.2023.1263836 Received 20 July 2023 Accepted 21 August 2023 Published 12 September 2023 Volume 11 - 2023 Edited by Paul Henderson, University of Edinburgh, United Kingdom Reviewed by Tudor Lucian Pop, University of Medicine and Pharmacy Iuliu Hatieganu, Romania Bin Wang, Shenzhen Childrens Hospital, China Updates Copyright 2023 Jiachen, Paul Kwong Hang, Kenneth Kak Yuen and Vincent Chi Hang
These include anti-inflammatory effects within the trigeminal pain system, reduction of intracranial pressure through decreased CSF [cerebrospinal fluid] secretion, and modulation of CGRP [calcitonin gene-related peptide] (a key migraine-promoting signaling molecule), Yuan said
Following that, the dose is progressively escalated at four-week intervals until reaching a maintenance dose of 2.4mg once weekly [5]
Contact our team for bulk pricing, product information, or research consultation.
Myasoedova, E., Crowson, C